ALNY - SHAREHOLDER ALERT: Levi & Korsinsky LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals Inc. | Benzinga
NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients. Analysts commenting on the approval noted the FDA was not overly positive and "emphasized the small treatment effects and was seemingly negative on clinical meaningfulness."
Following this news, Alnylam's stock price fell by $18.59 per share, or approximately 4% to close at $193.06 per share.
Further, on ...